R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Immunology - Discovery (46)

Modality Indication Targets Stage Company Project No. Detail
1 Development of an Extracellular Vesicle-Based In Vivo Macrophage Reprogramming Therapy for Inflammatory Bowel Disease with Enhanced Targeted Delivery Efficiency of NLRP3 ASO
Gene & Nucleic acids IBD(Ulcerative colitis) NLRP3, CD47 Hit SHIFTBIO.INC RS-2025-02122993
2 Development of Placental Growth Factor-Targeting Monoclonal Antibodies for Overcoming Autoimmune Diseases through Dual Control of Immune and Vascular Systems
Antibody Rheumatoid Arthritis, Multiple Sclerosis PlGF (Placental growth factor) Hit The Catholic University of Korea RS-2024-00462449
3 Development of LCN2 inhibitor for multiple sclerosis
Small molecules Multiple sclerosis Lipocalin 2 (LCN2) Hit K-MEDI hub RS-2024-00335752
4 Development of an sFasL-targeted antibody therapy for treating arthritis that is non-responsive or resistant to TNFα inhibitors
Antibody Rheumatoid Arthritis sFas L Hit Seoul National University RS-2023-00259272
5 Development of Hit/Lead compound using PKCη inhibitory drugs for treating multiple sclerosis
Small molecules Multiple Sclerosis PKCη Hit Hanyang University RS-2023-00217324
6 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Small molecules Psoriasis Cannabinoid 1 receptor Hit Ajou University RS-2023-00217308
7 Development of STAT6 blocking therapeutic drug in systemic sclerosis with targeting profibrotic T cells and fibroblasts
Small molecules Systemic Sclerosis STAT6 Hit The catholic university, medical college, LaTIM (Lab of Translational ImmunoMedicine) RS-2023-00217274
8 Therapeutic exosome development in Inflammatory Bowel Disease (IBD)
 with CARD9/TRIM62 Protein-Protein Interaction (PPI) inhibition activity
Other-Bio. Inflammatory Bowel Disease CARD9, TRIM62 Hit ILIAS Biologics Inc. HN22C0582
9 Generation of hit/lead compounds to treat multiple sclerosis by targeting formyl peptide receptor
rProtein Multiple Sclerosis FPR Hit Sungkyunkwan University HN22C0255
10 Development of anti-fibrosis therapeutics for systemic sclerosis using SOS1- RAS interaction-specific blockade
Small molecules Systemic Sclerosis SOS1/RAS Hit Kyungpook National University HN21C0307
11 Discovery study of CR-E1 targeting psoriasis lead compounds by regulating Th17 mechanism
Small molecules Psoriasis CR-E1 Hit Curogen Technology HN21C0250
12 Development of SCED-based lead compounds for atopic dermatitis
Small molecules Atopic dermatitis EGR1 Hit Konkuk University HN21C0984
13 Identification of a Lead Compound for the Treatment of Skin Immune Diseases Using Next-Generation TPD Technology Targeting STAT3
TPD Atopic dermatitis (Skin immune disease) STAT3 Lead Genexine, Inc. RS-2025-25455457
14 Discovery of lead compounds for multiple sclerosis via inflammation modulation induced by PKM2 tetramerization
Small molecules Multiple sclerosis PKM2 Lead Hanyang University ERICA RS-2025-02223325
15 Discovery research for a first-in-class lead live-microbial gene therapy to control gut-GVHD
Other-Bio. GVHD (Graft-versus-Hose Disease) Regulatory T cells Lead Liveome Inc. RS-2024-00460623
16 Developing lead substance of X family-targeted antibody therapy in treating acute graft-versus-host disease
Antibody Graft-verus-host disease Novel immune modulatory proteins expressed on the surface of activated T cells Lead Sungkyunkwan University School of Medicine RS-2024-00333055
17 Lead selection of allergen non.binding hybrid immunoglobulin E for the treatment of allergic severe asthma
Antibody Asthma FcεRIα Lead FatiAbGen Co., Ltd. RS-2023-00284138
18 Discovery of Selective IRAK4 Degrader based on Protac Technology
TPD Systemic Lupus Erythematosus IRAK4 Lead College of Pharmacy, Gachon University RS-2023-00218618
19 Evaluation of drug efficacy and discovery of pharmacodynamics biomarkers of a new anti-CD40 antibody lead compound (PB101) for the treatment of Pemphigus, a rare intractable skin disease
Antibody Pemphigus CD40 Lead PB Immune Therapeutics RS-2022-00165917
20 Discovery of Leads as LRRK2 inhibitors for the treat of Crohn’s disease
Small molecules Crohn's disease LRRK2 Lead Chung Ang University HN22C0690
21 Development of innovative monoclonal antibody drug targeting dimeric TCTP/HRF for treatment of chronic inflammatory diseases
Antibody Chronic Inflammatory diseases TCTP/HRF Lead Ewha Women's University HN22C0533
22 Discovery of Lead for a First-in-Class Drug Treating Inflammatory Bowel Disease (IBD)
Small molecules Ulcerative colitis, Crohn's disease PIN1 Lead PimedBio HN22C0056
23 Lead selection and optimization of therapeutic anti- CD40 antibody for the treatment of multiple sclerosis
Antibody Multiple Sclerosis CD40 Lead PB immune therapeutics HN21C1359
24 Discovery of lead small molecules to control NLRP3 inflammasome
Small molecules Psoriasis, Inflammatory disease NLRP3 Lead Ajou University HN21C1058
25 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Others-Synth. Psoriasis, Contact dermatitis Hyaluronic acid Lead Ajou University HN21C0958
26 Development of TYK2 pseudokinase domain selective inhibitor for autoimmune treatment
Small molecules Psoriasis, Rheumatoid Arthritis Tyk2 Lead CrystalGenomic Inc. HN21C0189
27 Development of highly selective STAT3 allosteric inhibitors as oral IBD therapies to overcome the limitations of existing treatments
Small molecules IBD STAT3 Candidate Huchembio Co., Ltd. RS-2026-25503669
28 **** inhibitor substance-based systemic lupus erythematosus new drug candidate substance development
Small molecules Systemic lupus erythematosus **** Candidate PROVIBIO RS-2026-25503404
29 Discovery of small-molecule drug candidates for the treatment of Fibrostenotic Crohn's Disease
Small molecules FSCD TG2 Candidate Huons RS-2026-25503256
30 Development of a First-in-Class IVIG Glyco-Based Ophthalmic Eye Drop Candidate for Uveitis Treatment
rProtein Non-infectious Uveitis, Ocular Surface Inflammatory Diseases Ocular Innate immune regulatory receptor pathway Candidate INUS IMMUNE Co., Ltd. RS-2026-25503178
31 Discovery of a First-in-Class Oral Small-Molecule TL1A Inhibitor for Inflammatory Bowel Disease
Small molecules IBD TL1A Candidate ILAb Co., Ltd. RS-2026-25501736
32 Development of best-in-class anti-OX40 therapeutic antibody candidate for the treatment of atopic dermatitis
Antibody Atopic Dermatitis OX40 Candidate Centenaire Biosciences, Inc. RS-2025-25453439
33 Development of Selective TYK2 Allosteric Domain Inhibitors as Candidate Therapeutics for Autoimmune Diseases
Small molecules Inflammatory autoimmune disease TYK2 Candidate AZothBio, Inc. RS-2025-02213331
34 Development of an oral EGR1-targeted candidate for atopic dermatitis
Small molecules Atopic dermatitis EGR-1 Candidate AgeraMedi, INC. RS-2025-02213190
35 Development of Selective STAT6 Inhibitors for Eosinophilic Esophagitis and Th2 Inflammatory Immune Diseases
Small molecules EoE, Type 2 inflammatory autoimmune disease STAT6 Candidate JW C&C Research Laboratories RS-2025-02183026
36 Preclinical Candidate Development of Innovative Drugs Targeting NLRP3 Inflammasome Inhibition for Inflammatory Bowel Disease
Small molecules Ulcerative colitis NLRP3 Candidate JMackem Co., Ltd RS-2025-02173120
37 Development of Candidate Antibody to Block Resistin for Treatment of Inflammatory Bowel Disease
Antibody IBD RESISTIN Candidate KIM CELL&GENE RS-2025-02132982
38 Development of a multi-specific target fusion protein for autoimmune disease
rProtein psoriasis, psoriatic arthritis IL-17A, IL-17F and TNFa Candidate CUROGEN RS-2024-00462095
39 Developing the drug candidates for psoriasis treatment using small molecule with IRAK.1/4 inhibition
Small molecules Psoriasis IRAK1/4 Candidate Dongwha Pharm Co.,Ltd. RS-2023-00284094
40 Development of a novel RIPK1 inhibitor for autoimmune disease(BSC.1300)
Small molecules Autoimmune diseases RIPK1 Candidate BiSiChem RS-2023-00259271
41 Development of a therapeutic agent for ulcerative colitis based on the regeneration mechanism of intestinal mucosa using an AIbased drug development platform
Small molecules Ulcerative colitis 15.PGDH Candidate Innovo Therapeutics, Inc. RS-2023-00258490
42 Candidate selection for development of an immunosuppressive monoclonal antibody against allergic disease
Antibody Atopic dermatitis CD200R1 Candidate AIMEDBIO Inc. RS-2023-00218545
43 Novel antibody candidate for rheumatoid arthritis
Antibody Rheumatoid Arthritis WARS1 Candidate MirimGene RS-2022-00166575
44 Candidate Selection of IL-2v-SAFA for the treatment of rare autoimmune disease
rProtein Systemic Lupus Erythematosus, IBD IL-2 Candidate AprilBio RS-2022-00165592
45 Discovery of non-clinical candidates of new PKM2 activator that cure inflammation and fibrosis at the same time through cell metabolism modulation
Small molecules Rheumatoid arthritis, IBD PKM2 Candidate Lmito Therapeutics HN21C0943
46 The generation of candidate for atopic dermatitis via selective STAT3 inhibition
Small molecules Atopic dermatitis STAT3 Candidate C&C Research Laboratories HN21C0543
BACK